The fact that UGP2 is downregulated and functions as a tumor suppressor in CRC (and similarly in HCC [10]) while being upregulated and acting as an oncogene in GBM [9] indicates that its biological effects are not inherently pro- or anti-tumorigenic; instead, they are differentially regulated depending on the type of cancer. Here, UGP2 is linked to hepatocellular carcinoma.